Outstanding effectiveness of paclitaxel-based technologies for the treatment of femoropopliteal artery occlusive disease on the potential expense of increased late all-cause mortality? No reason to panic
Vasa
.
2019 Mar;48(2):109-111.
doi: 10.1024/0301-1526/a000778.
Authors
Thomas Zeller
1
,
Elias Noory
1
,
Ulrich Beschorner
1
,
Tanja Böhme
1
,
Michel Mpj Reijnen
2
Affiliations
1
1 Department of Angiology, Universitäts-Herzzentrum Freiburg-Bad Krozingen, Bad Krozingen, Germany.
2
2 Department of Surgery, Rijnstate Hospital Arnhem, Arnhem, and Technical Medical Centre, University of Twente, Enschede, The Netherlands.
PMID:
30821214
DOI:
10.1024/0301-1526/a000778
No abstract available
MeSH terms
Angioplasty, Balloon*
Arterial Occlusive Diseases* / drug therapy
Femoral Artery
Humans
Paclitaxel / therapeutic use*
Popliteal Artery
Treatment Outcome
Vascular Patency
Substances
Paclitaxel